StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Neuroscience Therapeutic Area Total by Quarter

Neuroscience Therapeutic Area Total — U.S. operational growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson Neuroscience Therapeutic Area Total: 26.8% in Q3 2026, up 1.8 pts from a year earlier.

Latest, Q3 2026
26.8%
Period ended Sep 30, 2026
Change on a year earlier
+1.8 pts
25.0% in Q3 2025
History
24 quarters
Since Q4 2017
Sources
24
Documents cited below

Where the Q3 2026 figure comes from

“|| US | 1,733 | 1,367 | 26.8 | 26.8 | —”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeuroscience Therapeutic Area Total — U.S. operational growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202626.8%+1.8 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202620.5%-4.4 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202654.3%+62.4 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202525.4%+13.1 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202525.0%+19.4 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 202524.9%+17.8 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 2025-8.1%–Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202412.3%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q3 2024Sep 29, 20245.6%–Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 20247.1%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2021Apr 4, 20213.2%-0.1 ptsForm 8-K (a2021q1exhibit991final.htm, filed 2021-04-20) ↗
Q4 2020Jan 3, 20217.9%-5.3 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 2020-3.5%-24.2 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 202017.4%+13.6 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 20203.3%-12.7 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 201913.2%+18.8 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗

Cite this data

StockData. (2026). Johnson & Johnson Neuroscience Therapeutic Area Total (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta-neuroscience-us-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.